var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?d387e539c1f2d34f09a9afbac8032280"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })();

HIV

WHO at ICASA 2019

WHO launched HIV testing recommendations on the eve of World AIDS Day and ICASA

27 November 2019 - WHO is releasing new recommendations on HIV testing services on 27 November ahead of World AIDS and the International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA2019) taking place in Kigali, Rwanda on 2-7 December.

A midwife providing a woman with family planning counseling, and options at a health center, Senegal

WHO revises recommendations on hormonal contraceptive use for women at high HIV risk

29 August 2019 – WHO has revised its guidance on contraceptive use to reflect new evidence that women at high risk of HIV can use any form of reversible contraception, including progestogen-only injectables, implants and intrauterine devices, without an increased risk of HIV infection. However, as these contraceptive methods do not protect against HIV and other sexually transmitted infections, the guideline emphasizes that correct and consistent use of condoms should be used where there is a risk of STIs, including HIV.

Jonathan Torgovnik
Event-driven PrEP option for men who have sex with men allow people greater choice, flexibility and convenience for HIV prevention.

Event-driven or daily PrEP: ANRS Prévenir study confirms that these two biomedical prevention strategies are very effective and safe

23 July 2019 – The findings from the ANRS Ipergay and Prévenir studies provided evidence for the World Health Organization to update its recommendation for oral PrEP to include an option of event-driven (also called on-demand) dosing for men who have sex with men. A technical brief detailing the evidence and considerations for event-driven PrEP implementation is being released by WHO during the 10th IAS conference in Mexico City.

PrEPster/Ajamu Studio
WHO at IAS 2019 press conference, 22 July 2019

WHO recommends dolutegravir as preferred HIV treatment option in all populations

66顺彩票app22 July 2019 | Mexico City – Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential. New data from two large clinical trials comparing the efficacy and safety of DTG and efavirenz (EFV) in Africa have now expanded the evidence base. The risks of neural tube defects are significantly lower than what the initial studies may have suggested.

WHO/T.Namjilsuren
WHO at IAS 2019

WHO at IAS 2019

July 2019 – WHO will hold high-level events and several key sessions at the upcoming 10th IAS Conference on HIV Science, taking place in Mexico from 21-24 July 2019. WHO will also release 11 new products and publications, present 15 scientific posters and participate in 2 press conferences.

Community health worker during a home visit, providing family planning services and options to women in the community, Uganda

New study finds no link between HIV infection and contraceptive methods

13 June 2019 – A large clinical research study conducted in four African countries found no significant difference in risk of HIV infection among women using one of three highly effective, reversible contraceptive methods. Published today in the Lancet, the study showed that each method had high levels of safety and effectiveness in preventing pregnancy, with all methods well-accepted by the women using them.

Jonathan Torgovnik


HIV data



WHO HIV apps

HIV Tx app

HIV treatment and care guidelines app.

More HIV apps


Towards UHC to end AIDS

Global health sector strategies on HIV, viral hepatitis and STIs

HIV stories

Lina's story: Hope for women living with HIV in Malaysia

Stay connected

WHO, Department of HIV

Sign-up for newsletters

Register in our Stakeholders’ database by sending an email to hiv-aids[at]who.int with subject line “Sign-up for newsletters”. You will receive regular updates from our Department.

963彩票开户 677彩票开户 7072彩票开户 66顺彩票总代理 7073彩票地址 689彩票邀请码 7073彩票网址 7073彩票登录 8炫彩彩票app 9188彩票代理